TriSalus Life Sciences (NASDAQ:TLSI) Issues Quarterly Earnings Results, Meets Estimates

TriSalus Life Sciences (NASDAQ:TLSI) released its earnings results on Thursday. The company reported ($0.35) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.35), Zacks reports. The firm had revenue of $8.26 million during the quarter, compared to analysts’ expectations of $8.12 million. TriSalus Life Sciences updated its FY 2025 guidance to EPS.

TriSalus Life Sciences Price Performance

NASDAQ TLSI opened at $5.62 on Friday. TriSalus Life Sciences has a 1-year low of $3.50 and a 1-year high of $10.42. The firm has a market capitalization of $171.37 million, a P/E ratio of -2.26 and a beta of 0.48. The business’s 50-day simple moving average is $5.40 and its 200-day simple moving average is $4.74.

Insider Buying and Selling

In other TriSalus Life Sciences news, CFO James Emmett Young purchased 6,000 shares of the firm’s stock in a transaction that occurred on Wednesday, February 5th. The stock was purchased at an average cost of $5.65 per share, with a total value of $33,900.00. Following the transaction, the chief financial officer now owns 30,000 shares in the company, valued at approximately $169,500. This trade represents a 25.00 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Mary T. Szela acquired 5,030 shares of the business’s stock in a transaction on Wednesday, January 29th. The stock was bought at an average cost of $5.03 per share, for a total transaction of $25,300.90. Following the completion of the transaction, the chief executive officer now directly owns 439,249 shares of the company’s stock, valued at $2,209,422.47. This trade represents a 1.16 % increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last quarter, insiders acquired 54,856 shares of company stock valued at $294,608. 32.80% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

Several brokerages recently issued reports on TLSI. Canaccord Genuity Group reissued a “buy” rating and set a $11.00 price objective on shares of TriSalus Life Sciences in a research note on Friday. Lake Street Capital assumed coverage on TriSalus Life Sciences in a report on Thursday, February 13th. They set a “buy” rating and a $10.00 price objective on the stock. Roth Mkm reiterated a “buy” rating and issued a $11.00 target price on shares of TriSalus Life Sciences in a research note on Friday, January 24th. Finally, Cantor Fitzgerald began coverage on TriSalus Life Sciences in a research note on Tuesday, December 17th. They issued an “overweight” rating and a $10.00 price target on the stock. Eight research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat.com, TriSalus Life Sciences presently has an average rating of “Buy” and an average target price of $11.56.

About TriSalus Life Sciences

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.